New Hope for 80,000 England Vitiligo Sufferers

A groundbreaking new cream, Ruxolitinib, has received approval for use on the NHS in England, marking a significant development for the estimated 80,000 individuals living with vitiligo. This marks the first licensed treatment for the chronic skin condition to be recommended by the National Institute for Health and Care Excellence (Nice).

The cream, known by the brand name Opzelura, is recommended for patients aged 12 and over with non-segmental vitiligo affecting the face, particularly when other topical treatments have proven ineffective or unsuitable. It is applied twice daily to calm the immune system's attack on pigment-producing cells, thereby allowing the skin to regain its natural colour.

Clinical trials have demonstrated the cream's efficacy, with patients being four times more likely to experience restoration of their natural facial skin colour compared to those on a placebo. Patients also reported that the topical application was less time-consuming than existing light therapy treatments, which often require frequent hospital visits.

Experts and patient advocates have lauded the approval, with Helen Knight from Nice stating it acknowledges the profound impact vitiligo can have on a person's quality of life. Abigail Hurrell of The Vitiligo Society described it as a "historic milestone" and a "fundamental shift towards the equitable care" the community deserves. NHS England expects the cream to be available within three months of Nice publishing its final guidance.